Palvella Therapeutics
PVLA
13 hedge funds and large institutions have $33.8M invested in Palvella Therapeutics in 2015 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
27% less capital invested
Capital invested by funds: $46.6M → $33.8M (-$12.8M)
Top Buyers
Top Sellers
PVLA Hedge Fund Activity: Q3 2015 in Review
13 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2015, worth a combined $33.8M — down 27% from $46.6M a quarter earlier.
Fund positioning in PVLA was balanced in Q3 2015: 7 funds opened new positions, 7 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Omega Fund Management, opening a new position worth an estimated $6.93M. The largest seller was Green Owl Capital Management, exiting entirely with an estimated $1.24M sold.
- 13 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $33.8M of Palvella Therapeutics stock for Q3 2015, down 27% quarter-over-quarter.
- 7 funds opened new Palvella Therapeutics positions in Q3 2015 and 7 closed out, a net change of 0 holders.
- The largest Palvella Therapeutics buyer in Q3 2015 was Omega Fund Management, an estimated $6.93M added.
- The largest Palvella Therapeutics seller in Q3 2015 was Green Owl Capital Management, an estimated $1.24M sold.
Based on aggregated 13F filings for Q3 2015.